Viral Vector-Based Cell & Gene Therapy CDMO Market is projected to reach USD $ Billion in 2025, at a $% CAGR by driving industry size, share, segments research, top cpany analysis, trends and forecast report 2025 to 2031.

Viral Vector-Based Cell & Gene Therapy CDMO Market Growth and Outlook 2025-2031

The global Viral Vector-Based Cell &amp; Gene Therapy CDMO market size is predicted to grow from US$ 154 million in 2025 to US$ 326 million in 2031; it is expected to grow at a CAGR of 13.4% from 2025 to 2031.Viral vector-based cell and gene therapy CDMO refers to a contract research and development and production organization (CDMO) that focuses on providing professional R&amp;D and production services for viral vector-based cell and gene therapy products to biopharmaceutical companies. These services cover everything from the design and optimization of viral vectors to large-scale production in accordance with GMP (Good Manufacturing Practice) standards, as well as product quality control and safety assurance.United States market for Viral Vector-Based Cell &amp; Gene Therapy CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.China market for Viral Vector-Based Cell &amp; Gene Therapy CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.Europe market for Viral Vector-Based Cell &amp; Gene Therapy CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.Global key Viral Vector-Based Cell &amp; Gene Therapy CDMO players cover AGC Biologics, Lonza, Charles River Laboratories, Thermo Fisher Scientific, SK pharmteco, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.LPI (LP Information)' newest research report, the &ldquo;Viral Vector-Based Cell &amp; Gene Therapy CDMO Industry Forecast&rdquo; looks at past sales and reviews total world Viral Vector-Based Cell &amp; Gene Therapy CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Viral Vector-Based Cell &amp; Gene Therapy CDMO sales for 2025 through 2031. With Viral Vector-Based Cell &amp; Gene Therapy CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vector-Based Cell &amp; Gene Therapy CDMO industry.This Insight Report provides a comprehensive analysis of the global Viral Vector-Based Cell &amp; Gene Therapy CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&amp;A activity. This report also analyses the strategies of leading global companies with a focus on Viral Vector-Based Cell &amp; Gene Therapy CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms&rsquo; unique position in an accelerating global Viral Vector-Based Cell &amp; Gene Therapy CDMO market.This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vector-Based Cell &amp; Gene Therapy CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vector-Based Cell &amp; Gene Therapy CDMO.This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vector-Based Cell &amp; Gene Therapy CDMO market by product type, application, key players and key regions and countries.Segmentation by Type:&nbsp;&nbsp;&nbsp; Adeno-associated Viral &nbsp;&nbsp;&nbsp; Adenoviral &nbsp;&nbsp;&nbsp; Lentiviral &nbsp;&nbsp;&nbsp; RetroviralSegmentation by Application:&nbsp;&nbsp;&nbsp; Gene Therapy &nbsp;&nbsp;&nbsp; Cell Therapy &nbsp;&nbsp;&nbsp; Vaccine DevelopmentThis report also splits the market by region:&nbsp;&nbsp;&nbsp; Americas&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil&nbsp;&nbsp;&nbsp; APAC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia&nbsp;&nbsp;&nbsp; Europe&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia&nbsp;&nbsp;&nbsp; Middle East &amp; Africa&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC CountriesThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.&nbsp;&nbsp;&nbsp; AGC Biologics &nbsp;&nbsp;&nbsp; Lonza &nbsp;&nbsp;&nbsp; Charles River Laboratories &nbsp;&nbsp;&nbsp; Thermo Fisher Scientific &nbsp;&nbsp;&nbsp; SK pharmteco &nbsp;&nbsp;&nbsp; Exothera

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size (2020-2031) &nbsp;2.1.2 Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031) &nbsp;2.1.3 World Current &amp; Future Analysis for Viral Vector-Based Cell &amp; Gene Therapy CDMO by Country/Region (2020, 2024 &amp; 2031) &nbsp;2.2 Viral Vector-Based Cell &amp; Gene Therapy CDMO Segment by Type &nbsp;2.2.1 Adeno-associated Viral &nbsp;2.2.2 Adenoviral &nbsp;2.2.3 Lentiviral &nbsp;2.2.4 Retroviral &nbsp;2.3 Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size by Type &nbsp;2.3.1 Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size CAGR by Type (2020 VS 2024 VS 2031) &nbsp;2.3.2 Global Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size Market Share by Type (2020-2025) &nbsp;2.4 Viral Vector-Based Cell &amp; Gene Therapy CDMO Segment by Application &nbsp;2.4.1 Gene Therapy &nbsp;2.4.2 Cell Therapy &nbsp;2.4.3 Vaccine Development &nbsp;2.5 Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size by Application &nbsp;2.5.1 Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031) &nbsp;2.5.2 Global Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size Market Share by Application (2020-2025)3 Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size by Player &nbsp;3.1 Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size Market Share by Player &nbsp;3.1.1 Global Viral Vector-Based Cell &amp; Gene Therapy CDMO Revenue by Player (2020-2025) &nbsp;3.1.2 Global Viral Vector-Based Cell &amp; Gene Therapy CDMO Revenue Market Share by Player (2020-2025) &nbsp;3.2 Global Viral Vector-Based Cell &amp; Gene Therapy CDMO Key Players Head office and Products Offered &nbsp;3.3 Market Concentration Rate Analysis &nbsp;3.3.1 Competition Landscape Analysis &nbsp;3.3.2 Concentration Ratio (CR3, CR5 and CR10) &amp; (2023-2025) &nbsp;3.4 New Products and Potential Entrants &nbsp;3.5 Mergers &amp; Acquisitions, Expansion4 Viral Vector-Based Cell &amp; Gene Therapy CDMO by Region &nbsp;4.1 Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size by Region (2020-2025) &nbsp;4.2 Global Viral Vector-Based Cell &amp; Gene Therapy CDMO Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size Growth (2020-2025) &nbsp;4.4 APAC Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size Growth (2020-2025) &nbsp;4.5 Europe Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size Growth (2020-2025) &nbsp;4.6 Middle East &amp; Africa Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size Growth (2020-2025)5 Americas &nbsp;5.1 Americas Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size by Country (2020-2025) &nbsp;5.2 Americas Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size by Type (2020-2025) &nbsp;5.3 Americas Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil6 APAC &nbsp;6.1 APAC Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size by Region (2020-2025) &nbsp;6.2 APAC Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size by Type (2020-2025) &nbsp;6.3 APAC Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia7 Europe &nbsp;7.1 Europe Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size by Country (2020-2025) &nbsp;7.2 Europe Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size by Type (2020-2025) &nbsp;7.3 Europe Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia8 Middle East &amp; Africa &nbsp;8.1 Middle East &amp; Africa Viral Vector-Based Cell &amp; Gene Therapy CDMO by Region (2020-2025) &nbsp;8.2 Middle East &amp; Africa Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size by Type (2020-2025) &nbsp;8.3 Middle East &amp; Africa Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Size by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers &amp; Growth Opportunities &nbsp;9.2 Market Challenges &amp; Risks &nbsp;9.3 Industry Trends10 Global Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Forecast &nbsp;10.1 Global Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast by Region (2026-2031) &nbsp;10.1.1 Global Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast by Region (2026-2031) &nbsp;10.1.2 Americas Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.1.3 APAC Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.1.4 Europe Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.1.5 Middle East &amp; Africa Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.2 Americas Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast by Country (2026-2031) &nbsp;10.2.1 United States Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.2.2 Canada Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.2.3 Mexico Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.2.4 Brazil Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.3 APAC Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast by Region (2026-2031) &nbsp;10.3.1 China Viral Vector-Based Cell &amp; Gene Therapy CDMO Market Forecast &nbsp;10.3.2 Japan Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.3.3 Korea Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.3.4 Southeast Asia Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.3.5 India Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.3.6 Australia Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.4 Europe Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast by Country (2026-2031) &nbsp;10.4.1 Germany Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.4.2 France Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.4.3 UK Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.4.4 Italy Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.4.5 Russia Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.5 Middle East &amp; Africa Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast by Region (2026-2031) &nbsp;10.5.1 Egypt Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.5.2 South Africa Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.5.3 Israel Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.5.4 Turkey Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast &nbsp;10.6 Global Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast by Type (2026-2031) &nbsp;10.7 Global Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast by Application (2026-2031) &nbsp;10.7.1 GCC Countries Market Viral Vector-Based Cell &amp; Gene Therapy CDMO Forecast11 Key Players Analysis &nbsp;11.1 AGC Biologics &nbsp;11.1.1 AGC Biologics Company Information &nbsp;11.1.2 AGC Biologics Viral Vector-Based Cell &amp; Gene Therapy CDMO Product Offered &nbsp;11.1.3 AGC Biologics Viral Vector-Based Cell &amp; Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.1.4 AGC Biologics Main Business Overview &nbsp;11.1.5 AGC Biologics Latest Developments &nbsp;11.2 Lonza &nbsp;11.2.1 Lonza Company Information &nbsp;11.2.2 Lonza Viral Vector-Based Cell &amp; Gene Therapy CDMO Product Offered &nbsp;11.2.3 Lonza Viral Vector-Based Cell &amp; Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.2.4 Lonza Main Business Overview &nbsp;11.2.5 Lonza Latest Developments &nbsp;11.3 Charles River Laboratories &nbsp;11.3.1 Charles River Laboratories Company Information &nbsp;11.3.2 Charles River Laboratories Viral Vector-Based Cell &amp; Gene Therapy CDMO Product Offered &nbsp;11.3.3 Charles River Laboratories Viral Vector-Based Cell &amp; Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.3.4 Charles River Laboratories Main Business Overview &nbsp;11.3.5 Charles River Laboratories Latest Developments &nbsp;11.4 Thermo Fisher Scientific &nbsp;11.4.1 Thermo Fisher Scientific Company Information &nbsp;11.4.2 Thermo Fisher Scientific Viral Vector-Based Cell &amp; Gene Therapy CDMO Product Offered &nbsp;11.4.3 Thermo Fisher Scientific Viral Vector-Based Cell &amp; Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.4.4 Thermo Fisher Scientific Main Business Overview &nbsp;11.4.5 Thermo Fisher Scientific Latest Developments &nbsp;11.5 SK pharmteco &nbsp;11.5.1 SK pharmteco Company Information &nbsp;11.5.2 SK pharmteco Viral Vector-Based Cell &amp; Gene Therapy CDMO Product Offered &nbsp;11.5.3 SK pharmteco Viral Vector-Based Cell &amp; Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.5.4 SK pharmteco Main Business Overview &nbsp;11.5.5 SK pharmteco Latest Developments &nbsp;11.6 Exothera &nbsp;11.6.1 Exothera Company Information &nbsp;11.6.2 Exothera Viral Vector-Based Cell &amp; Gene Therapy CDMO Product Offered &nbsp;11.6.3 Exothera Viral Vector-Based Cell &amp; Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.6.4 Exothera Main Business Overview &nbsp;11.6.5 Exothera Latest Developments 12 Research Findings and Conclusion

Report	Global Viral Vector-Based Cell & Gene Therapy CDMO Market Growth (Status and Outlook) 2025-2031
Selected License	Multi ID: LPI3070

Buyer Information

Order Summary